- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Ganciclovir implant and oral ganciclovir, Cidofovir intravenous
- Device · Drug
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 19
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2665–2688
of 184,974
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hearing Loss, Adult-Onset, Hearing Aids
- Interventions
- Airpod Pro as hearing assistive technology
- Device
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richardson, Texas
- Conditions
- HPV-Related Squamous Cell Carcinoma
- Interventions
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
- Drug
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more
- Conditions
- H Pylori Infection, H Pylori Gastritis, Gastric Cancer
- Interventions
- PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Relapsed or Refractory Classical Hodgkin Lymphoma
- Interventions
- Sabestomig (AZD7789)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 101 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more
- Conditions
- Cutaneous Angiosarcoma
- Interventions
- Paclitaxel, Radiation therapy, Research blood draw
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HIV, Alcohol Use, Medication Adherence
- Interventions
- Immediate PLUS intervention, Wait-list PLUS intervention
- Behavioral
- Lead sponsor
- Hunter College of City University of New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19, Influenza A, Influenza B
- Interventions
- Panbio™
- Diagnostic Test
- Lead sponsor
- Abbott Rapid Dx
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Chronic Neurogenic Pain
- Interventions
- Transcranial magnetic stimulation, Sham
- Device · Other
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Glioblastoma
- Interventions
- enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED), Non-enzyme inducing antiepileptic drugs (NEIAED)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypotension
- Interventions
- Mespere Venus 1000 CVP System
- Device
- Lead sponsor
- Mespere Lifesciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dry Eye Disease
- Interventions
- OK-101, Placebo
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
- Conditions
- HIV Infections, Osteopenia, Osteoporosis
- Interventions
- Zoledronate, Zoledronate placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Obesity
- Interventions
- HIFT
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Anastomotic Leak, Fistula, Postoperative Leak, Postoperative Pancreatic Fistula, POPF
- Interventions
- NERv's Inline Device
- Device
- Lead sponsor
- FluidAI Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- extracorporeal photopheresis, laboratory biomarker analysis
- Procedure · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Prostate Cancer
- Interventions
- FACBC, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 95 Years · Male only
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Scabies
- Interventions
- Permethrin Cream, 5%, Elimite
- Drug
- Lead sponsor
- Mayne Pharma International Pty Ltd
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Miami, Florida • Richland, Washington
- Conditions
- Asthma in Children
- Interventions
- View PACCI-ED and referral recommendations
- Other
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Heart Failure
- Interventions
- Furoscix Infusor
- Combination Product
- Lead sponsor
- scPharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Sylmar, California • Bridgeport, Connecticut • Tampa, Florida + 5 more
- Conditions
- Lu-177 PSMA
- Interventions
- Lu-177, SPECT
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- Project 3, Phase 2: Clinical Trial
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Tallahassee, Florida • Champaign, Illinois • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- TTI-622, Daratumumab Hyaluronidase-fihj
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- hypofractionated radiation therapy, cisplatin, etoposide, 3-dimensional conformal radiation therapy, laboratory biomarker analysis
- Radiation · Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio